Added successfully to RFQ list

Added successfully to compare list

Our clients

Cell cycle acts as a relay station, connecting growth signalling networks with the initiation of DNA synthesis, and is therefore a potentially attractive therapeutic target. Assessing cell cycle distribution and proliferation is essential to study cell growth, differentiation, senescence and apoptosis. This helps to evaluate the underlying mechanisms, therapeutic efficacies of anticancer drugs and can be indicative of wider effects upon the cells, often used in the broader context or in conjunction with other target engagement assays.

cell cycle analysis_o2h discovery

Proliferating cells sequentially undergo transition through G1 – S – G2 and M phases, and under certain circumstances enter G0, as resting or quiescent state.  During DNA damage, the progression of cell cycle is interrupted at certain checkpoints leading to failed chromosomal alignment and mitotic arrest or delays. These can be characterized at individual stages to exactly pinpoint disruption of the normal processes.  o2h scientists can implement flow cytometry-based analysis to profile mitotic pathways and evaluate your compounds for cancer therapies. Whole-cell staining with propidium iodide (PI) and antibodies towards specific proteins or surface markers helps to concurrently analyse cellular characteristics within distinct cell populations G0/G1, S, and G2/M. The software helps to quantitatively determine phase distribution along with characteristics like  ploidy, apoptosis, senescence, cell type etc.

Case Study

The cell cycle can be divided into 5 main stages: G₀ phase where cells are resting and not undergoing any division, G₁ phase where cells are preparing to undergo DNA replication, S phase where cells are actively replicating their DNA, G₂ phase where cells have completed DNA replication and M phase where cells are undergoing mitosis to split into 2 daughter cells. At o2h, we have developed flow cytometry-based assays which allow the cell cycle phase of cells to be discovered and any alterations to these that result from treatment detected.

Figure 1: Cell cycle stages of HeLa cells in exponential growth phase in culture determined by staining of DNA content.

These stages can also be manipulated in culture to trap cells in one part of the cell cycle or to enrich for certain populations. Figure 2 shows the effects of a double thymidine block on the progression of cells through the cell cycle. As can be seen, this traps the majority of cells into the G₀/G₁ phase before releasing the cells allows them to progress through the cell cycle.

Figure 2: The effects of a thymidine block on cell cycle progression in HeLa cells. Left panel shows cells which have undergone a double thymidine block, the majority of cells are trapped in the early G₀/G₁ phases of the cycle. The middle panel shows the cells 2 hours after the release of the block where the majority of cells are in S phase. The right panel shows the cell cycle stage 8 hours after release where most of the cells have progressed into the G₂/M phase of the cell cycle.

To gain additional insight into the stages of the cell cycle, it is possible to combine DNA content staining with other markers which can separate cell cycle stages, such as Phospho-Histone H3 to distinguish the G₂ and M phases. As can be seen in figure 3, a relatively small proportion of cells are in M phase actively undergoing mitosis, and this can be enriched by using nocodazole, an agent that traps cells in the mitotic phase. Being able to detect cells in the M phased can be used to investigate the rate of cell division which is linked to a range of therapeutic opportunities.

Figure 3: Separation of the G₂ and M phases of the cell cycle by phosphor-Histone H3 and PI staining. HeLa cells growing in culture treated with vehicle (right 2 panels) or nocodazole (left 2 panels) and co-stained for DNA content and phosphor-histone H3 (Ser10). This shows that nocodazole traps cells in the M phase and that pH3 can be used to separate the G₂ and M phases.

At o2h discovery, we are experts in cellular and biochemical assays giving us the ability to combine the types of cell cycle and DNA ploidy analysis shown here with other assays including cell death and phenotypic screens, allowing us to provide you with excellent layers of depth of analysis with a high throughput in a bespoke manner to fit your needs.

To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.

our team

Sunil

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

Sunil's Biography

Read more

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University


Connect on linkedin

prashant shah

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant's Biography

Read more

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant is a serial entrepreneur in life sciences and tech in which one of those companies was acquired by a public company. He is currently active in seed investing (a portfolio of ~50 companies), product/IP development, services, and building lab/office infrastructure. The early career was with the Strategy group at Accenture. He has a BEng, an MSc, in which he worked on the Human Genome Program at the Sanger Centre, and an MPhil in Management from the Judge Institute. Prashant is also a General Partner in the o2h SEIS/EIS Human Health Funds.


Connect on linkedin

Andy Morley

Andy Morley

Chief Scientific Officer

Andy's Biography

Read more

Andy Morley

Chief Scientific Officer

Andy is a highly experienced and accomplished Medicinal Chemist with over 25 years of experience in major pharmaceutical companies such as Sanofi-Aventis and AstraZeneca. He has extensive experience across all phases of drug discovery and has played a key role in the development of five candidates that have reached clinical trials. Andy is a prolific author and inventor, with over 55 publications and patents to his name. Since 2013, he has been working full-time with o2h Limited, where he leads the scientific evaluation of investment opportunities and provides scientific support. He has also served as CSO for two early-stage collaborations within the o2h Ventures portfolio, demonstrating his ability to successfully guide drug discovery projects from concept to clinical development.


Connect on linkedin

David Davies - o2h

David Davies

Head of Medicinal Chemistry

David's Biography

Read more

David Davies

Head of Medicinal Chemistry

David Davies has 25 years of experience in medicinal chemistry within the pharmaceutical industry with a focus on the antibacterial area (clavulanates, penicillinates, pseudomonates and bacterial topoisomerase inhibitors). He previously worked at GSK and currently holds a part-time academic position at University College London (UCL). He served as the Head of Medicinal Chemistry at Antabio for nearly a decade, specialising in antibacterial research, and has extensive experience managing chemistry projects in multiple countries including France, UK, India and China. He is the inventor of 40 patents and has authored 37 publications.


Connect on linkedin

o2h group launched revolutionary project management app for drug discovery

o2h group launched revolutionary project management app for drug discovery. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules.

the influencer biotech bootcamp

Hauxton House, Mill Scitech Park, Cambridge

The world’s first biotech bootcamp, including the quintet influencer community that is the creative force driving biotech.

View more

latest news

Read about some of the most recent developments including research collaborations at o2h discovery

speak to a member of our team

Contact Us